抗生素对接受免疫检查点抑制剂治疗的日本转移性肾细胞癌患者预后的影响。
The Impact of Antibiotics on Prognosis of Metastatic Renal Cell Carcinoma in Japanese Patients Treated With Immune Checkpoint Inhibitors.
机构信息
Department of Urology, Kurume University School of Medicine, Kurume, Japan
Gustave Roussy Cancer Campus, Villejuif, France.
出版信息
Anticancer Res. 2019 Nov;39(11):6265-6271. doi: 10.21873/anticanres.13836.
BACKGROUND/AIM: The present study aimed to examine the influence of antibiotics (AB) on the clinical outcomes of Japanese patients treated with immune check point inhibitors (ICIs) for metastatic renal cell carcinoma (RCC) patients.
PATIENTS AND METHODS
A total of 31 patients with metastatic RCC treated with ICIs from November 2016 to April 2019 were retrospectively reviewed and analyzed.
RESULTS
Five patients were treated with AB prior to ICIs treatment. Median progression free survival (PFS) of patients treated with AB vs. patients not treated with AB was 2.8 months and 18.4 months, respectively. The difference between PFS was statistically significant (p=0.0004). In multivariate analyses, AB use (p=0.0377) and presence of immune related adverse events (p=0.0042) were independent prognostic factors for PFS in association with ICIs therapy.
CONCLUSION
The use of AB before ICIs treatment was a predictor of poor ICIs response in metastatic RCC.
背景/目的：本研究旨在探讨抗生素（AB）对接受免疫检查点抑制剂（ICI）治疗的转移性肾细胞癌（RCC）患者临床结局的影响。
患者与方法
回顾性分析了 2016 年 11 月至 2019 年 4 月期间接受 ICI 治疗的 31 例转移性 RCC 患者。
结果
5 例患者在接受 ICI 治疗前接受了 AB 治疗。接受 AB 治疗的患者与未接受 AB 治疗的患者的无进展生存期（PFS）分别为 2.8 个月和 18.4 个月，差异具有统计学意义（p=0.0004）。多因素分析显示，AB 使用（p=0.0377）和免疫相关不良反应的存在（p=0.0042）是与 ICI 治疗相关的 PFS 的独立预后因素。
结论
ICI 治疗前使用 AB 是转移性 RCC 患者对 ICI 反应不良的预测因素。
Zotero 插件